Research using a second-generation androgen-receptor targeting agent is now underway on the male patient population that is at risk of dying of prostate cancer called castrate-resistant prostate cancer (CRPC).
The ATLAS study, led by global principal investigator, Howard M. Sandler, Chair of the Department of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles, is expected to fully enroll 1500 patients by 2020 with a study completion date in 2026.
As reported in OncologyLive, ATLAS is aiming to provide better upfront disease control, with the goal of reducing the number of men who enter into the castrate-resistant prostate cancer stage.
Study researchers are hoping the results of a late stage efficacy and safety study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.
Posted in: Cancer